Skip to main content
. 2018 Oct 25;73:e327. doi: 10.6061/clinics/2018/e327

Table 4.

Outcomes.

Outcomes Control n=51 GDT n=48 p-value
Primary outcomes
    Scr difference 8h 0.10 [0.00-0.37] 0.10 [-0.10-0.40] 0.482
    Scr difference day 1 0.00 [-0.10-0.30] 0.10 [-0.20-0.60] 0.960
    Scr difference day 2 0.10 [-0.14-0.60] 0.17 [-0.25-0.80] 0.768
    Scr difference day 3 0.10 [-0.30-0.54] 0.10 [-0.35-0.70] 0.914
    RRT, n (%) 12 (25.0) 13 (27.1) 0.818
    8-h diuresis, ml 396.5 [200.0-500.0] 397.5 [252.5-537.5] 0.515
    AKI beyond 72h, n (%) 40 (78.4) 30 (62.5) 0.064
Secondary outcomes
    ICU LOS, days 7.5 [4.0-14.0] 7.0 [5.0-13.0] 0.579
    Hospital LOS, days 15.0 [10.0-25.5] 18.5 [10.0-27.0] 0.745
    ICU mortality, n (%) 15 (29.4) 10 (20.8) 0.326
    Hospital mortality, n (%) 26 (51.0) 15 (31.3) 0.048
    Composite, n (%) 44 (86.3) 37 (77.1) 0.178

SCr difference: Difference in serum creatinine level (8h and 1, 2, and 3 days after minus before initiation of goal-directed therapy). Composite: composite of hospital mortality, renal replacement therapy, or persistent renal functional impairment after 72h. Numbers are presented as n (%) or the median [IQR].